Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...

Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients ...

Summit Therapeutics Inc.'s faces FDA hurdles as its HARMONi study shows mixed results on ivonescimab. Click here to find out ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has ...

The natural history of chronic hepatitis B virus (HBV) infection is driven by complex interactions among virological, host, ...